Increased Oversight of Drug Precursors

Summary#

This is a proposed package of changes to the Precursor Control Regulations and to Schedule IX to the Controlled Drugs and Substances Act, published in the Canada Gazette, Part I on June 28, 2025. The aim is to give Health Canada, border and police agencies new tools to detect and stop the diversion or import of chemical precursors and equipment used to make illegal fentanyl and other synthetic drugs. The government estimates the measures would cost about $2.04 million in present value over 10 years (about $290,093 per year).

What it does#

• Requires licensed and registered dealers to report suspicious transactions to Health Canada in writing within 72 hours of becoming aware of them. Reports must be kept for 2 years.

  • Dealers would be protected from civil action for good‑faith reports and get limited protection against self‑incrimination for those reports and for loss/theft notices.

• Requires licensed and registered dealers to take “reasonable steps” to reduce the risk that employees will help divert precursors.

  • Employers must consider whether staff with access to precursors have, in the past 10 years, convictions for specified drug or criminal offences.
  • The rule is flexible about how businesses do this; records of the steps taken must be kept for 2 years.

• Reinstates and expands sale limits for products containing ephedrine or pseudoephedrine:

  • Natural health products and some non‑prescription drugs with those ingredients would generally only be sold to licensed dealers, pharmacists, health care practitioners or hospitals.
  • Single‑ingredient ephedrine/pseudoephedrine products would have to be kept out of public self‑selection (e.g., behind the counter). Combination products could be sold on store shelves only where a pharmacist is available on request. Online sales are covered the same way (pharmacist must be available by phone/text/video if requested).

• Gives the Minister of Health more flexible powers:

  • The Minister could add, change or remove licence/registration conditions at any time (with notice and an opportunity to be heard, except in urgent cases).
  • The Minister could partially suspend specific activities on a licence or registration immediately if there are reasonable grounds to do so.
  • The Minister could add conditions to transit and transhipment permits when issued.

• Expands import controls on drug‑manufacturing equipment by adding component parts (punches, moulds and dies for pill presses and encapsulators) to Schedule IX so those parts must be registered before importation. Importers would have to show proof of registration to customs. Health Canada estimates about 1,200 such component parts are imported annually.

• Repeals a separate Ministerial Order about sale rules for ephedrine/pseudoephedrine products once the PCR changes come into force, to avoid duplication.

Note: this is a proposal (published in Part I). The text says the rules would come into force when published in Canada Gazette, Part II. Interested parties were given 45 days to comment.

Who's affected#

• Licensed and registered dealers that handle precursors (Health Canada counts 429 licensed/registered sites).
• Importers of pill‑press or encapsulator component parts (estimated 1,200 parts imported per year).
• Pharmacies and pharmacists, and to a lesser extent community retailers that currently sell some non‑prescription products containing ephedrine or pseudoephedrine.
• Small businesses in the precursor supply chain (the analysis estimates 386 small businesses would be affected).
• Health Canada, Canada Border Services Agency (CBSA) and law enforcement partners such as the RCMP, who would use the new information and authorities.
• The general public could notice changes in how certain over‑the‑counter decongestants are sold.

If the source is unclear: the proposal describes protections for reporters and some procedural safeguards, but details about exactly how Health Canada will handle and triage reports, or how individual investigations would be run in partnership with police, are not fully spelled out in the published document.

Why it matters#

• The changes are aimed at making it harder for organized crime to import precursors or build clandestine labs that produce fentanyl and other synthetic drugs. The government points to an ongoing overdose crisis (about 51,000 opioid‑related deaths and related harms between January 2016 and September 2024, with about 75% of opioid deaths involving fentanyl) as the context for this action.
• For businesses, the rules add new reporting, record‑keeping and personnel‑screening steps and therefore extra administrative and compliance costs. The government estimates total costs at about $2.04 million present value over 10 years (about $290,093 per year) and expects small businesses to bear a share of that burden (estimated average cost per affected small business about $3,890 over the 10‑year period).
• For pharmacies and consumers, some commonly available cold and decongestant products could move behind the counter or require pharmacist interaction, which may change convenience and access—something the consultation flagged as a concern for rural and remote communities.
• For public safety, the proposal gives authorities faster, more targeted tools (for example, partial licence suspensions and immediate conditions in urgent cases) to respond to diversion risks. That could help disrupt domestic production and distribution of illegal synthetic drugs.